Category survey

Regulation of BACE1 transcytosis in hippocampal neurons Investments < €500k United States of America 2016    

Discovery of LXR Agonists via Pharmacophore Space Mining Investments < €500k United States of America 2016    

Small molecule therapeutics for Alzheimers Disease Investments < €500k United States of America 2016    

Anti-RPS23RG1 Nanoantibody as Novel Therapeutic and Research Reagents for Alzheimer’s Disease. Investments < €500k United States of America 2016    

Lead Optimization of CRAC Channel Inhibitors for the Treatment of Alzheimers Disease Investments < €500k United States of America 2016    

Target Engagement Biomarkers for Alzheimers Therapeutics Investments < €500k United States of America 2016    

Triggered Palliative Care for Advanced Dementia: A Pilot Study Investments < €500k United States of America 2016    

Optimizing Outcome Measures for Clin. Trials in Pre-Clinical Alzheimers Disease Investments < €500k United States of America 2016    

MySearch: Purposeful Individual and Independent Activities for Persons with Early to Moderate Stage Alzheimer’s Disease and Related Dementias Investments < €500k United States of America 2016    

Memory Lane: A neuro-exergame to mitigate cognitive decline in later life Investments < €500k United States of America 2016    

Mobile Application to Deliver Personalized Nutrition for the Prevention of Alzheimers Disease Investments < €500k United States of America 2016    

Computational modeling of semantic decline in Alzheimers disease Investments < €500k United States of America 2016    

Differences in Pain Between Alzheimers Disease and Vascular Dementia in Older Females Investments < €500k United States of America 2016    

Auditory Cognitive Training in Persons with Mild Cognitive Impairment Investments < €500k United States of America 2016    

Linking Olfactory deficits to Neurodegenerative Disorders Investments < €500k United States of America 2016    

Molecular mechanisms of ganglion cell loss in Alzheimers disease Investments < €500k United States of America 2016    

NMDA RECEPTOR MODULATORS AS NOOTROPIC THERAPIES IN AGING BRAIN Investments < €500k United States of America 2016    

Episodic memory protection in apolipoprotein E (APOE) knockout rats Investments < €500k United States of America 2016    

Genetic and Lifestyle Determinants of Cognitive Resilience in Midlife Investments < €500k United States of America 2016    

Animal model of impaired autoregulation for study of age related vascular cognitive impairment Investments < €500k United States of America 2016    

The mechanism of cognitive reserve in bilingualism Investments < €500k United States of America 2016    

Mediator as a transducer of amyloid precursor protein-dependent nuclear signaling Investments < €500k United States of America 2016    

Genetic and Functional Analysis of Nested AD Risk Genes CTNNA3 and LRRTM3 Investments < €500k United States of America 2016    

Investigation of the Tau Gene Network and Quantitative Alzheimers Disease Biomarker Phenotypes Investments < €500k United States of America 2016    

Admixture mapping in late-onset Alzheimer’s disease Investments < €500k United States of America 2016    

Mapping AD Memory Failure: Molecules to Connectivity of Brain Network Investments < €500k United States of America 2016    

A machine learning approach to identify Alzheimers disease therapeutic targets Investments < €500k United States of America 2016    

Novel Aminoadamantane Nitrates for the Treatment of Neurological Diseases Investments < €500k United States of America 2016    

Screening for enhancers of sAPPalpha Investments < €500k United States of America 2016    

New piperazines effecting Abeta oligomer displacement from neuronal receptors Investments < €500k United States of America 2016    

Targeting Neurovascular Dysfunction in AD Investments < €500k United States of America 2016    

Activators of Nrf2 Translation in Alzheimers Disease Investments < €500k United States of America 2016    

Preclinical assessment of an ABCA1 agonist as a novel therapeutic for AD Investments < €500k United States of America 2016    

A flavonoid gamma-secretase modulator (GSM) reduces beta-amyloid and tau pathologies in the AD mice Investments < €500k United States of America 2016    

Small molecule Parkin activators to treat Alzheimers Disease Investments < €500k United States of America 2016    

Double-blocking Anti-crosslinking Strategy for AD Drug Development Investments < €500k United States of America 2016    

Structure-based Identification and Functional Characterization of SSH1 Inhibitors Investments < €500k United States of America 2016    

Development of peptide inhibitors for neuroinflammation and neurodegeneration Investments < €500k United States of America 2016    

2016-2018 Drug Discovery for Neurodegeneration Conferences Investments < €500k United States of America 2016    

Target Identification for Novel Small Molecule Therapeutic for Alzheimers disease Investments < €500k United States of America 2016    

Discovery of New Chemical Entities for Alzheimers Disease Tauopathy Investments < €500k United States of America 2016    

Near-infrared molecular imaging for monitoring therapy in AD mouse models Investments < €500k United States of America 2016    

AGE-RELATED BIOMARKET CHANGES IN CEREBROSPINAL FLUID Investments < €500k United States of America 2016    

Resolving Factors in Alzheimers Disease Investments < €500k United States of America 2016    

New PET imaging agent for monitoring treatment response in Alzheimers disease Investments < €500k United States of America 2016    

In vivo permeability of the human blood-cerbrospinal fluid barrier in dementia Investments < €500k United States of America 2016    

Novel Strategies for Blood-based Biomarkers for AD: Role of Genetic Variation in a Multivariate Framework Investments < €500k United States of America 2016    

Tau Imaging in Atypical AD Investments < €500k United States of America 2016    

Imaging Innate Immune Responsiveness of Microglia in Alzheimers Disease Brain Investments < €500k United States of America 2016    

A method for early and easy detection of Alzheimers disease Investments < €500k United States of America 2016